S1P and MS — Key Articles

FTY720 requires vitamin B(12)-TCN2-CD320 signaling in astrocytes to reduce disease in an animal model of multiple sclerosis

Jonnalagadda D, Kihara Y, Groves A, Ray M, Saha A, Ellington C, Lee-Okada HC, Furihata T, Yokomizo T, Quadros EV, Rivera R, Chun J. Cell Reports. 2023

Type: Article, Publications, Highlighted Articles, Year: 2023ScienceSitesDecember 8, 2023S1P and MS

Single-Nucleus RNA-seq of Normal-Appearing Brain Regions in Relapsing-Remitting vs. Secondary Progressive Multiple Sclerosis: Implications for the Efficacy of Fingolimod

Kihara Y, Zhu Y, Jonnalagadda D, Romanow W, Palmer C, Siddoway B, Rivera R, Dutta R, Trapp BD, Chun J.. Frontiers in Cellular Neuroscience. 2022.

Type: Article, Year: 2018, Publications, Highlighted ArticlesScienceSitesSeptember 30, 2022SCT, S1P and MS

Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P(1) -selective modulation

Kihara Y, Jonnalagadda D, Zhu Y, Ray M, Ngo T, Palmer C, Rivera R, Chun J. FASEB Journal 2022.

Gwen KaeserJanuary 5, 2022S1P and MS

S1P(2)-Gα(12) Signaling Controls Astrocytic Glutamate Uptake and Mitochondrial Oxygen Consumption

Jonnalagadda D, Kihara Y, Rivera R, Chun J. eNeuro 2021.

Highlighted Articles, Publications, Type: Article, Year: 2021Gwen KaeserDecember 3, 2021S1P and MS

Fingolimod: Direct CNS Effects of Sphingosine 1- Phosphate (S1P) Receptor Modulation and Implications in Multiple Sclerosis Therapy

Groves A, Kihara Y, Chun J. J Neurol Sci 2013;328(1-2):9-18.

Type: Review, Year: 2013, Publications, Highlighted ArticlesScienceSitesSeptember 30, 2021S1P and MS

A Functionally Defined in Vivo Astrocyte Population Identified By c-Fos Activation in a Mouse Model of Multiple Sclerosis Modulated by S1P Signaling: Immediate Early Astrocytes (ieAstrocytes)

Groves A, Kihara Y, Jonnalagadda D, Rivera R, Kennedy G, Mayford M, Chun J. eNeuro 2018; 5(5).

Type: Article, Year: 2018, Publications, Highlighted ArticlesScienceSitesSeptember 30, 2021S1P and MS

FTY720 (Fingolimod) Efficacy in an Animal Model of Multiple Sclerosis Requires Astrocyte Sphingosine 1-Phosphate Receptor (S1P1) Modulation

Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, Chun J. Proc Natl Acad Sci USA 2011;108(2):751-756.

Type: Article, Year: 2011, Publications, Highlighted ArticlesScienceSitesSeptember 30, 2021S1P and MS

Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders

Chun J, Kihara Y, Jonnalagadda D, Blaho VA. Annu Rev Pharmacol Toxicol 2019;59:149-170.

Type: Review, Year: 2019, Publications, Highlighted ArticlesScienceSitesSeptember 30, 2021S1P and MS

Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects

Chun J, Giovannoni G, Hunter SF. Drugs 2021.

Publications, Year: 2021, Highlighted ArticlesScienceSitesSeptember 30, 2021S1P and MS